Results

1–10 of 89 results for Anti-VEGF Agents

Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study
J. Fernando Arevalo, MD, PhD, FACS, FASRS
Annual Meeting Talks
2020
Tricks of Anti-VEGF Treatment for Retinopathy of Prematurity: How and when to Do It? When to Wait? When to Redo?
HUSEYIN YETIK, MD, PROFESSOR OF OPHTHALMOLGY
On Demand Cases, Courses, and Papers
2019
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
A Randomized Trial of Intravitreous Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)
Raj K. Maturi, MD
Updates from the Field
2021
Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial
Peter A. Campochiaro, MD
Updates from the Field
2021
AMD Take Home Panel
Annual Meeting Talks
2020
Diabetic Retinopathy Take Home Panel
Annual Meeting Talks
2020
Instrumentation & Devices Symposium 2
Annual Meeting Talks
2020
Wet AMD 6 Symposium
Annual Meeting Talks
2020
Wet AMD 5 Symposium
Annual Meeting Talks
2020